Cencora (COR) Revenue — Quarter Ended Sep 30, 2024
Revenue for the quarter increased compared to the preceding quarter and the same quarter one year ago. The company operates as a global pharmaceutical sourcing and distribution services firm.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q4
Revenue for the quarter increased compared to the preceding quarter and the same quarter one year ago. The company operates as a global pharmaceutical sourcing and distribution services firm.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$79.1B
Revenue reported for this quarter.
Quarter-over-quarter
+6.5%
Change from the immediately preceding quarter.
Year-over-year
+14.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$294B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $72.3B | +15.0% |
| Mar 31, 2024 | $68.4B | +7.8% |
| Jun 30, 2024 | $74.2B | +10.9% |
| Sep 30, 2024 | $79.1B | +14.7% |
Revenue performance
Revenue in the reporting period was higher than in the immediately prior quarter.
Quarterly comparison
Compared to the same quarter one year earlier, revenue also rose. The year-over-year increase was more pronounced than the quarter-over-quarter change.
What to watch
The filing notes increased seasonal inventory needs during the December and March quarters, which could influence future revenue comparisons.